Clinical Trial Update: The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update for AZD1722 in constipation-predominant irritable bowel syndrome (IBS-C) completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Constipation-predominant Irritable Bowel Syndrome

Drugs mentioned

• AZD1722

Snippet

Sponsor: Ardelyx | Conditions: Constipation Predominant Irritable Bowel Syndrome | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-01-10